DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
In the reply filed 8/26/26, Applicants amended claims 1-10, 12-13 are amended. Claims 19-24 are newly added.
Claims 1-13 and 19-24 are pending and under consideration.
Please note that this is a 2nd NF rejection due to the NEW double patenting rejection presented below.
Claim Rejections - Withdrawn
The rejection of claims 2 and 10 under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends is withdrawn due to amendment of claim 1.
The rejection of claims 9-13 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for alleviating hair loss associated alopecia with SEQ ID NO: 1 or SEQ ID NO: 2, does not reasonably provide enablement for prevention and treatment of all forms of alopecia is withdrawn due to amendment of the claims.
The rejection of claims 1-8 rejected under 35 U.S.C. 101 because the claimed invention is not directed to patent eligible subject matter is withdrawn as the naturally occurring protein from Nympaea colorata does not have the claimed function of alleviating alopecia symptoms.
Claim Rejections - 35 USC § 112-NEW
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 21-23 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. This is a New rejection necessitated by amendment of the claims.
Claims 21-23 recite the limitation “wherein the peptide consists of peptides of SEQ ID NO: 1 and SEQ ID NO: 2 in combination”. This limitation is indefinite because it is unclear if the limitation means SEQ ID NO: 1 and SEQ ID NO: 2 are used in combination in the composition (i.e. 2 separate peptides in the composition) OR if the peptide consists of a single peptide consisting of SEQ ID NO: 1 and SEQ ID NO: 2 (i.e. a fusion protein consisting on SEQ ID NO: 1 and 2). It is impossible to determine the metes and bounds of the claims.
Claim Rejections - 35 USC § 102-Maintained and Modified
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
The rejection of claims 1 and 3-8 under 35 U.S.C. 102(a)(1) as being anticipated by Reiser et al. (USPN 9,144,594 9/29/2015) as evidenced the Medical dictionary (<Pomade | definition of pomade by Medical dictionary> accessed 10/29/26) is maintained and extended to NEW claims 19 and 20.
Amended Claim 1 is drawn to a composition comprising one or more scalp-derived peptides selected from the group consisting of amino acid sequences of SEQ ID NO: 1 (RKLW) and SEQ ID NO: 2 (RQLW) with the ability to alleviate alopecia symptoms, and which is configured for external skin administration. Please note that the transitional phrase “comprising” is interpreted as open. MPEP 2111.03 states the transitional term “comprising”, which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. Because the instant specification fails to provide a limiting definition of the phrase “comprising”, the broadest reasonable interpretation of amended claim 1 includes sequences in which SEQ ID NO: 1 and SEQ ID NO: 2 are embedded and does not exclude additional, unrecited elements.
Amended claim 2 is drawn to the composition of claim 1, wherein the peptide consists of the peptide of SEQ ID NO: 2. The limitation “consisting of” is interpreted as closed. Therefore, the claim is interpreted to be drawn to the peptide consisting of 4 amino acids and cannot be embedded in a larger sequence.
With respect to claims 1 and 3-8, Reiser et al. teach SEQ ID NO: 33, which is 4 amino acids and is identical to instantly claimed SEQ ID NO: 1 (see sequence below). With respect to the limitation “with the ability to alleviate alopecia symptoms" and the limitations of claims 3-8, please note that it is regarded that "intended use" of a composition or product will not further limit claims drawn to a composition or product. See, e.g., Ex parte Masham, 2 USPQ2d 1647 (1987) and In Re Hack 114, USPQ 161. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim limitation. In the instant case, the specification discloses the exact sequence has the ability to alleviate alopecia symptoms. Importantly, the peptide from the reference would inherently have all of the activities and properties of SEQ ID NO: 1. The MPEP § 2112 states: “Once a reference teaching product appearing to be substantially identical is made the basis of a rejection, and the Examiner presents evidence or reasoning tending to show inherency, the burden shifts to the Applicant to show an unobvious difference ‘[t]he PTO can require an Applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his [or her] claimed product. Whether the rejection is based on inherency’ under 35 U.S.C. 102, on prima facie obviousness’ under 35 U.S.C. 103, jointly or alternatively, the burden of proof is the same…[footnote omitted].” The burden of proof is similar to that required with respect to product-by-process claims. In re Fitzqerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980) (quoting In re Best, 562 F.2d 1252, 1255, 195 USPQ 430,433- 34 (CCPA 1977)).” In other words, the peptide of Reiser et al. is identical to instantly claimed 1. Therefore, the same peptide would inherently have the same properties. Moreover, MPEP 2112.01 states: “Products of identical chemical composition cannot have mutually exclusive properties.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Importantly, MPEP 2112 states: “[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer” and “There is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference
PNG
media_image1.png
712
830
media_image1.png
Greyscale
With respect to the new limitation “configured for external skin administration”, Reiser et al. teach the pharmaceutical compositions may be administered topically (as by powders, ointments, drops or transdermal patch)(top of p. 28).
With respect to NEW claim 19, Reiser et al. teach the pharmaceutical composition may contain suitable buffering agents, and suitable preservatives (col. 27, lines 19-23; col.28, lines 33-34).
With respect to NEW claim 20, Reiser et al. teach the pharmaceutical compositions may be administered topically (as by powders, ointments, drops or transdermal patch)(top of p. 28). As evidenced by the medical dictionary, a pomade is an ointment containing medicaments. Please note that MPEP 2131.01 states: that an extra reference or evidence can be used to show an inherent characteristic of the thing taught by the primary reference. In the instant case, the medical dictionary is relied upon only to establish that a pomade is an ointment containing medicaments. Therefore, the ointment of Reiser et al. containing the peptides meets the limitation.
Furthermore, the limitation “in the form of a hair tonic, a hair cream…or an eyelash nutrient” please note that it is regarded that "intended use" of a composition or product will not further limit claims drawn to a composition or product. See, e.g., Ex parte Masham, 2 USPQ2d 1647 (1987) and In Re Hack 114, USPQ 161. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim limitation.
Response to Arguments
Applicant's arguments filed 8/26/26 have been fully considered but they are not persuasive. Applicants argue that Reiser does not disclose or suggest a composition that is configured for topical administration. Applicants argue that the composition is topically administered composition rather than a parenterally administered composition.
This argument was considered but is not persuasive for the reasons presented in in the 103 rejection above. In particular, the teachings that Reiser teaches the composition can be administered topically. For the reasons presented above, the rejection is maintained.
Double Patenting-NEW
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-13 and 19-24 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over 1-12 of copending Application No. 19/608,877(reference application). This is a NEW rejection because the copending Application was filed after mailing of the NF rejection.
Although the claims at issue are not identical, they are not patentably distinct from each other because the copending Application claims a composition comprising SEQ ID NO: 1 and 2, which are identical to instantly claimed SEQ ID NO: 1 and 2. The copending Application claims the composition has efficacy in preventing, alleviating or treating hair loss from alopecia. The copending application claims the peptides is a topical skin preparation in the form of a hair cream, hair lotion etc. Therefore, the copending claims anticipated the instant claims .
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Conclusion
Claims 1-13 and 19-24 are rejected.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TARA L MARTINEZ whose telephone number is (571)270-1470. The examiner can normally be reached Mon-Fri 8:00-5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko Garyu can be reached at (571)270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TARA L MARTINEZ/ Primary Examiner, Art Unit 1654